Very early administration of glucose-insulin-potassium by emergency medical service for acute coronary syndromes: Biological mechanisms for benefit in the IMMEDIATE Trial

Harry P. Selker, William Harris, Charles E. Rackley, Julian B. Marsh, Robin Ruthazer, Joni R. Beshansky, Eric J. Rashba, Inga Peter, Lionel H. Opie

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Aims In the IMMEDIATE Trial, intravenous glucose-insulin-potassium (GIK) was started as early as possible for patients with suspected acute coronary syndrome by ambulance paramedics in communities. In the IMMEDIATE Biological Mechanism Cohort substudy, reported here, we investigated potential modes of GIK action on specific circulating metabolic components. Specific attention was given to suppression of circulating oxygen-wasting free fatty acids (FFAs) that had been posed as part of the early GIK action related to averting cardiac arrest. Methods We analyzed the changes in plasma levels of FFA, glucose, C-peptide, and the homeostasis model assessment (HOMA) index. Results With GIK, there was rapid suppression of FFA levels with estimated levels for GIK and placebo groups after 2 hours of treatment of 480 and 781 μmol/L (P <.0001), even while patterns of FFA saturation remained unchanged. There were no significant changes in the HOMA index in the GIK or placebo groups (HOMA index: placebo 10.93, GIK 12.99; P =.07), suggesting that GIK infusions were not countered by insulin resistance. Also, neither placebo nor GIK altered endogenous insulin secretion as reflected by unchanging C-peptide levels. Conclusion These mechanistic observations support the potential role of FFA suppression in very early cardioprotection by GIK. They also suggest that the IMMEDIATE Trial GIK formula is balanced with respect to its insulin and glucose composition, as it induced no endogenous insulin secretion.

Original languageEnglish (US)
Pages (from-to)168-175
Number of pages8
JournalAmerican Heart Journal
Volume178
DOIs
StatePublished - Aug 1 2016
Externally publishedYes

Fingerprint

Emergency Medical Services
Acute Coronary Syndrome
Nonesterified Fatty Acids
Potassium
Insulin
Glucose
Placebos
Homeostasis
C-Peptide
Allied Health Personnel
Ambulances
Heart Arrest
Insulin Resistance
Oxygen

ASJC Scopus subject areas

  • Medicine(all)
  • Cardiology and Cardiovascular Medicine

Cite this

Very early administration of glucose-insulin-potassium by emergency medical service for acute coronary syndromes : Biological mechanisms for benefit in the IMMEDIATE Trial. / Selker, Harry P.; Harris, William; Rackley, Charles E.; Marsh, Julian B.; Ruthazer, Robin; Beshansky, Joni R.; Rashba, Eric J.; Peter, Inga; Opie, Lionel H.

In: American Heart Journal, Vol. 178, 01.08.2016, p. 168-175.

Research output: Contribution to journalArticle

Selker, Harry P. ; Harris, William ; Rackley, Charles E. ; Marsh, Julian B. ; Ruthazer, Robin ; Beshansky, Joni R. ; Rashba, Eric J. ; Peter, Inga ; Opie, Lionel H. / Very early administration of glucose-insulin-potassium by emergency medical service for acute coronary syndromes : Biological mechanisms for benefit in the IMMEDIATE Trial. In: American Heart Journal. 2016 ; Vol. 178. pp. 168-175.
@article{40c5676ab7aa4f4a8d8702b49458c544,
title = "Very early administration of glucose-insulin-potassium by emergency medical service for acute coronary syndromes: Biological mechanisms for benefit in the IMMEDIATE Trial",
abstract = "Aims In the IMMEDIATE Trial, intravenous glucose-insulin-potassium (GIK) was started as early as possible for patients with suspected acute coronary syndrome by ambulance paramedics in communities. In the IMMEDIATE Biological Mechanism Cohort substudy, reported here, we investigated potential modes of GIK action on specific circulating metabolic components. Specific attention was given to suppression of circulating oxygen-wasting free fatty acids (FFAs) that had been posed as part of the early GIK action related to averting cardiac arrest. Methods We analyzed the changes in plasma levels of FFA, glucose, C-peptide, and the homeostasis model assessment (HOMA) index. Results With GIK, there was rapid suppression of FFA levels with estimated levels for GIK and placebo groups after 2 hours of treatment of 480 and 781 μmol/L (P <.0001), even while patterns of FFA saturation remained unchanged. There were no significant changes in the HOMA index in the GIK or placebo groups (HOMA index: placebo 10.93, GIK 12.99; P =.07), suggesting that GIK infusions were not countered by insulin resistance. Also, neither placebo nor GIK altered endogenous insulin secretion as reflected by unchanging C-peptide levels. Conclusion These mechanistic observations support the potential role of FFA suppression in very early cardioprotection by GIK. They also suggest that the IMMEDIATE Trial GIK formula is balanced with respect to its insulin and glucose composition, as it induced no endogenous insulin secretion.",
author = "Selker, {Harry P.} and William Harris and Rackley, {Charles E.} and Marsh, {Julian B.} and Robin Ruthazer and Beshansky, {Joni R.} and Rashba, {Eric J.} and Inga Peter and Opie, {Lionel H.}",
year = "2016",
month = "8",
day = "1",
doi = "10.1016/j.ahj.2016.03.026",
language = "English (US)",
volume = "178",
pages = "168--175",
journal = "American Heart Journal",
issn = "0002-8703",
publisher = "Mosby Inc.",

}

TY - JOUR

T1 - Very early administration of glucose-insulin-potassium by emergency medical service for acute coronary syndromes

T2 - Biological mechanisms for benefit in the IMMEDIATE Trial

AU - Selker, Harry P.

AU - Harris, William

AU - Rackley, Charles E.

AU - Marsh, Julian B.

AU - Ruthazer, Robin

AU - Beshansky, Joni R.

AU - Rashba, Eric J.

AU - Peter, Inga

AU - Opie, Lionel H.

PY - 2016/8/1

Y1 - 2016/8/1

N2 - Aims In the IMMEDIATE Trial, intravenous glucose-insulin-potassium (GIK) was started as early as possible for patients with suspected acute coronary syndrome by ambulance paramedics in communities. In the IMMEDIATE Biological Mechanism Cohort substudy, reported here, we investigated potential modes of GIK action on specific circulating metabolic components. Specific attention was given to suppression of circulating oxygen-wasting free fatty acids (FFAs) that had been posed as part of the early GIK action related to averting cardiac arrest. Methods We analyzed the changes in plasma levels of FFA, glucose, C-peptide, and the homeostasis model assessment (HOMA) index. Results With GIK, there was rapid suppression of FFA levels with estimated levels for GIK and placebo groups after 2 hours of treatment of 480 and 781 μmol/L (P <.0001), even while patterns of FFA saturation remained unchanged. There were no significant changes in the HOMA index in the GIK or placebo groups (HOMA index: placebo 10.93, GIK 12.99; P =.07), suggesting that GIK infusions were not countered by insulin resistance. Also, neither placebo nor GIK altered endogenous insulin secretion as reflected by unchanging C-peptide levels. Conclusion These mechanistic observations support the potential role of FFA suppression in very early cardioprotection by GIK. They also suggest that the IMMEDIATE Trial GIK formula is balanced with respect to its insulin and glucose composition, as it induced no endogenous insulin secretion.

AB - Aims In the IMMEDIATE Trial, intravenous glucose-insulin-potassium (GIK) was started as early as possible for patients with suspected acute coronary syndrome by ambulance paramedics in communities. In the IMMEDIATE Biological Mechanism Cohort substudy, reported here, we investigated potential modes of GIK action on specific circulating metabolic components. Specific attention was given to suppression of circulating oxygen-wasting free fatty acids (FFAs) that had been posed as part of the early GIK action related to averting cardiac arrest. Methods We analyzed the changes in plasma levels of FFA, glucose, C-peptide, and the homeostasis model assessment (HOMA) index. Results With GIK, there was rapid suppression of FFA levels with estimated levels for GIK and placebo groups after 2 hours of treatment of 480 and 781 μmol/L (P <.0001), even while patterns of FFA saturation remained unchanged. There were no significant changes in the HOMA index in the GIK or placebo groups (HOMA index: placebo 10.93, GIK 12.99; P =.07), suggesting that GIK infusions were not countered by insulin resistance. Also, neither placebo nor GIK altered endogenous insulin secretion as reflected by unchanging C-peptide levels. Conclusion These mechanistic observations support the potential role of FFA suppression in very early cardioprotection by GIK. They also suggest that the IMMEDIATE Trial GIK formula is balanced with respect to its insulin and glucose composition, as it induced no endogenous insulin secretion.

UR - http://www.scopus.com/inward/record.url?scp=84975852976&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84975852976&partnerID=8YFLogxK

U2 - 10.1016/j.ahj.2016.03.026

DO - 10.1016/j.ahj.2016.03.026

M3 - Article

C2 - 27502865

AN - SCOPUS:84975852976

VL - 178

SP - 168

EP - 175

JO - American Heart Journal

JF - American Heart Journal

SN - 0002-8703

ER -